iBio (IBIO) Stock Analysis & AI Equity Report
iBio (IBIO) overview
iBio (IBIO) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -35.1m; the year-end share price was 1.75 USD and market capitalisation was USD 97.5m. iBio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get iBio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About iBio
iBio is a clinical-stage biotechnology company using artificial intelligence and machine learning to develop antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases. Its pipeline includes a clinical-stage long-acting myostatin antibody and preclinical candidates, including antibodies targeting Activin E and a myostatin–Activin A bispecific antibody. The company conducts discovery and development work at its research laboratory in San Diego.
Generate the iBio report
iBio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for iBio and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on iBio
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.